Blume Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Blume Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-600	Closed	-$13K	–	226
2018 Q3	$13K	Hold	600	–	–	0.01%	158
2018 Q2	$15K	Hold	600	–	–	0.01%	155
2018 Q1	$10K	Hold	600	–	–	0.01%	176
2017 Q4	$11K	Hold	600	–	–	0.01%	185
2017 Q3	$11K	Sell	600 -118,980	-99%	-$2.68M	0.01%	193
2017 Q2	$3.97M	Buy	119,580 +10,900	+10%	+$337K	2.26%	19
2017 Q1	$3.49M	Buy	108,680 +25,565	+31%	+$872K	2.02%	22
2016 Q4	$3.01M	Buy	+83,115	New	+$3.32M	1.81%	24

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Blume Capital Management's TEVA Position: Q4 2018 in Review

Blume Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2018, closing a stake of 600 shares — an estimated $13K sold.

Blume Capital Management first reported a position in TEVA in Q4 2016 and held it in 8 quarters. The position peaked at $3.97M in Q2 2017. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Blume Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2018 after selling out during the quarter.
Blume Capital Management sold 600 Teva Pharmaceutical Industries Limited shares in Q4 2018, an estimated $13K.
Blume Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2016 and held it in 8 quarters.
Blume Capital Management's Teva Pharmaceutical Industries Limited position peaked at $3.97M in Q2 2017.
552 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2018.

Based on Blume Capital Management's 13F filing for Q4 2018, filed 5 Feb 2019.